Latest filings (excl ownership)
8-K
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
6 Jun 24
8-K
Regulation FD Disclosure
4 Jun 24
8-K
Regulation FD Disclosure
3 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
29 May 24
8-K
Other Events
15 May 24
424B5
Prospectus supplement for primary offering
15 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Regulation FD Disclosure
7 May 24
8-K
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 24
S-8
Registration of securities for employees
19 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
MAIA Biotechnology Announces $1.33 Million Private Placement
26 Mar 24
8-K
Other Events
25 Mar 24
424B5
Prospectus supplement for primary offering
25 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
D
$5.70 mm in equity / options / securities to be acquired, sold $2.92 mm, 19 investors
21 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
8-K
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
8 Mar 24
8-K
Other Events
6 Mar 24
8-K
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
27 Feb 24
8-K
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
23 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
30 Jan 24
8-K
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
18 Jan 24
8-K
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
21 Dec 23
D
$4.86 mm in equity / options / securities to be acquired, sold $4.86 mm, 3 investors
29 Nov 23
8-K
MAIA Biotechnology Announces $4 Million Registered Direct Offering
17 Nov 23
424B5
Prospectus supplement for primary offering
17 Nov 23
8-K
Entry into a Material Definitive Agreement
16 Nov 23
8-K
Termination of a Material Definitive Agreement
15 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
8-K
Other Events
13 Nov 23
8-K
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Other Events
30 Oct 23
8-K
MAIA Biotechnology Announces Share Repurchase Program
28 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
424B5
Prospectus supplement for primary offering
1 Sep 23
Latest ownership filings
4
Sergei Gryaznov
30 Apr 24
4
Jeffrey C Himmelreich
30 Apr 24
4
Vlad Vitoc
30 Apr 24
4
Ngar Yee Louie
26 Apr 24
4
Stan Smith
26 Apr 24
4
Stan Smith
2 Apr 24
4
Ngar Yee Louie
2 Apr 24
4
STEVEN M CHAOUKI
2 Apr 24
4
Ramiro Guerrero
2 Apr 24
4
Cristian Luput
2 Apr 24
4
Jean-Manasse Theagene
2 Apr 24
4
STEVEN M CHAOUKI
18 Mar 24
4
Stan Smith
15 Mar 24
4
Ngar Yee Louie
15 Mar 24
4
Cristian Luput
15 Mar 24
4
Ramiro Guerrero
15 Mar 24
4
Sergei Gryaznov
26 Jan 24
4
Vlad Vitoc
26 Jan 24
4
Jeffrey C Himmelreich
26 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
4
Stan Smith
3 Jan 24
4
Cristian Luput
3 Jan 24
4
Ngar Yee Louie
3 Jan 24
4
Ramiro Guerrero
3 Jan 24
4
STEVEN M CHAOUKI
3 Jan 24
4
Jean-Manasse Theagene
3 Jan 24
3
Jeffrey C Himmelreich
20 Nov 23
4
Jean-Manasse Theagene
3 Oct 23
4
Cristian Luput
3 Oct 23
4
Ngar Yee Louie
3 Oct 23
4
Ramiro Guerrero
3 Oct 23
4
STEVEN M CHAOUKI
3 Oct 23
4
Stan Smith
3 Oct 23
4
STEVEN M CHAOUKI
5 Jul 23
4
Ramiro Guerrero
5 Jul 23
4
Ngar Yee Louie
5 Jul 23
4
Cristian Luput
5 Jul 23
4
Jean-Manasse Theagene
5 Jul 23
4
Stan Smith
5 Jul 23
4
Vlad Vitoc
5 Jun 23